The global pigmented villonodular synovitis drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Pigmented villonodular synovitis (PVNS) is a joint problem that affects the hip or knee and causes the lining of a joint to be swollen and grow which harms the bone around the joint. However, it can also occur in the shoulder, ankle, elbow, hand or foot. The major factor driving the growth of the market is the increasing number of in-patients in hospitals suffering from rare conditions and growing demand for advanced treatment across the globe. Moreover, the market is also growing due to the increasing incidence of PVNS disease. According to the National Center for Biotechnology Information (NCBI), PVNS is a rare disease with a prevalence of 9.2 patients out of a million population.
To Request a Sample of our Report on Pigmented Villonodular Synovitis Drug Market: https://www.omrglobal.com/request-sample/pigmented-villonodular-synovitis-drug-market
Some major players operating in the market include Bristol-Myers Squibb Co., Daiichi Sankyo Co., Ltd., and Novartis International AG, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in August 2019, Daiichi Sankyo Co., Ltd. announced the approval of TURALIO (pexidartinib) from the US Food and Drug Administration (FDA). It is the first and only treatment for symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery in adult patients. TGCT is also called pigmented villonodular synovitis (PVNS).
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
Segment Covered-
- By Type
- By Application
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape- Bristol-Myers Squibb Co., Daiichi Sankyo Company, Ltd., and Novartis International AG, among others.
(Get 15% Discount on Buying this Report)
A full Report of Pigmented Villonodular Synovitis Drug Market is Available @ https://www.omrglobal.com/industry-reports/pigmented-villonodular-synovitis-drug-market
Global Pigmented Villonodular Synovitis Drug Market Report by Segment
By Type
- Cabiralizumab
- Emactuzumab
- Mcs-110
- Nilotinib
- Others
By Application
- Clinic
- Hospital
- Homecare
Global Pigmented Villonodular Synovitis Drug Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
